Flow cytometric evaluation of biomarkers

临床定量流式细胞术是一种新技术，利用专门的 抗体染色技术和荧光标准品来定量抗原表达， 不同的细胞群。流式细胞术单元使用该技术来 在接受各种抗原定向治疗的患者中定量肿瘤细胞抗原表达 治疗（例如治疗性抗体、CAR T细胞疗法）。流式细胞术测定是 快速而精确。这提高了NCI调查人员监测减少或 抗原表达增加，以及将抗体与肿瘤细胞的结合与 治疗反应。在治疗后立即定量荧光抗体结合还 允许用未标记的治疗剂精确测定抗原位点的饱和度 抗体的在治疗前、治疗期间和治疗后对抗原进行定量可以提供对以下方面的了解： 被新的治疗剂破坏的途径。因此，抗原定量是一个巨大的 NCI研究人员的资源在其他机构不可用。流式细胞术 测试也用于评估接受嵌合抗原受体（CAR）T细胞的患者， 在NCI治疗。它在评估对嵌合抗原受体（CAR）的反应中起着至关重要的作用 通过定量患者中的治疗性CAR T细胞的扩增， 同时监测肿瘤细胞的减少。此外，流式细胞术 该股还继续支持中央档案室艾滋病毒和艾滋病咨询分支处正在进行的研究， 包括开发新的生物标志物测定，如LANA1流式细胞术测定， HHV8相关B细胞淋巴瘤或淋巴增生性疾病的评价， 对原发性渗出性淋巴瘤的潜在治疗靶点，如CD38。

Clinical quantitative flow cytometry is a new technology that utilizes specialized antibody staining techniques and fluorescent standards to quantitate antigen expression by different cell populations within a sample. The Flow Cytometry Unit uses this technique to quantitate tumor cell antigen expression in patients undergoing various antigen directed therapies (e.g. therapeutic antibody, CAR T-cell therapy). The flow cytometric assays are rapid and very precise. This improves the ability of NCI investigators to monitor decrease or increase in antigen expression, as well as compare antibody binding to tumor cells to treatment response. Quantitation of fluorescent antibody binding immediately post therapy also allows precise determination of saturation of antigen sites with non labeled therapeutic antibody. Quantitation of antigens prior to, during and post therapy may provide insight into pathways disrupted by novel therapeutic agents. Antigen Quantitation is therefore a tremendous resource for NCI investigators that is not available at other institutions. Flow cytometric testing is also utilized to evaluate patients receiving chimeric antigen receptor (CAR) T cell therapy at NCI. It plays a vital role in assessing response to chimeric antigen receptor (CAR) T cell therapy by quantitating expansion of the therapeutic CAR T cells in the patient while at the same time monitoring the decrease in neoplastic cells. Additionally, the Flow Cytometry Unit also continues to support ongoing research in the CCR HIV and AIDS Malignancy Branch, including development of new biomarker assay, such as LANA1 flow cytometric assay, for evaluation of HHV8-associated B-cell lymphoma or lymphoproliferative disorders, and evaluation of potential therapeutic target, such as CD38, for primary effusion lymphoma.